4th Quarter - Report
DLA PIPER LLP (US) for GENENTECH USA, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development, approval, reimbursement, and pricing; patient assistance and access programs; privacy; and benefit redesign. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 5376, Build Back Better Act, drug pricing provisions.
Foreign entity interest: Roche Holdings, AG, interests are those of parent company.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES GREENWOOD | — |
| JAMIE ALEXEI GREGORIAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.